Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Guided Posters

Pituitary - Clinical

ea0041gp149 | Pituitary - Clinical | ECE2016

Impact of AIP and Gαi-2 proteins on clinical features of sporadic GH-secreting pituitary adenomas

Ritvonen Elina , Pitkanen Esa , Karppinen Atte , Vehkavaara Satu , Demir Hande , Paetau Anders , Schalin-Jantti Camilla , Karhu Auli

Introduction: In sporadic acromegaly, downregulation of AIP protein of the adenomas associates with invasive tumour features and reduced response to somatostatin analogue treatment. AIP is a regulator of Gαi signaling, but it is not known how the biological function of the Gαi pathway is controlled.Aim: To study somatic GNAS and AIP mutation status, AIP and Gαi-2 protein expressions, Ki67 proliferation indices, and clinical parameters in p...

ea0041gp150 | Pituitary - Clinical | ECE2016

Treatment of acromegaly increases BMD but reduces Trabecular Bone Score – a longitudinal study

Godang Kristin , Cristina Olarescu Nicoleta , Bollerslev Jens , Heck Ansgar

Background: Bone turnover is increased in active acromegaly. Despite normalization of bone turnover after treatment, the risk for vertebral fractures remains increased. Gonadal status, but not bone mineral density (BMD) is correlated to vertebral fracture incidence. Trabecular and cortical bone are differentially affected by GH and IGF-1. The trabecular bone score (TBS) is related to bone microarchitecture and provides further information not captured by BMD measurement.<p...

ea0041gp151 | Pituitary - Clinical | ECE2016

Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial

Fleseriu Maria , Melmed Shlomo , Mangal Brian , Strasburger Christian J , Biermasz Nienke R

Introduction: Although biochemical markers of acromegaly disease activity, including GH and IGF1, may fluctuate from day-to-day, biochemical treatment response in clinical trials is generally monitored using single-point analyses. Accordingly, longitudinal evaluations may assess patient status more accurately. In a phase 3 trial, oral octreotide capsules (OOC) demonstrated sustained composite endpoint GH and IGF1 response for ≤13 months in 151 patients with acromegaly pr...

ea0041gp152 | Pituitary - Clinical | ECE2016

Effects of hydrocortisone substitution on blood pressure – results from an RCT

Buning Jorien Werumeus , van Faassen Martijn , Brummelman Pauline , Dullaart Robin P F , van den Berg Gerrit , van der Klauw Melanie M , Kerstens Michiel N , Kobold Anneke C Muller , Kema Ido P , Wolffenbuttel Bruce H R , van Beek Andre P

Background: Patients with secondary adrenal insufficiency show increased risk of cardiovascular disease. Higher doses of glucocorticoid replacement are related to an unfavourable metabolic profile. In the absence of randomized controlled trials assessing the effect of hydrocortisone dose on haemodynamics and blood pressure regulation, we determined effects of a higher vs a lower glucocorticoid replacement dose on blood pressure, the renin-angiotensin-aldosterone system (RAAS) ...

ea0041gp153 | Pituitary - Clinical | ECE2016

Once-monthly injection of pasireotide LAR reduces urinary free cortisol (UFC) levels in patients with Cushing’s disease: Results from a randomised, multicentre, phase III trial

Newell-Price John , Petersenn Stephan , Biller Beverly M K , Roughton Michael , Ravichandran Shoba , Lacroix Andre

Background: Twice-daily formulation of pasireotide, a pituitary-directed therapy, is approved for treatment of Cushing’s disease. Here we present data from a phase III study designed to evaluate the more convenient once-monthly long-acting release (LAR) formulation of pasireotide (approved for acromegaly) in patients with Cushing’s disease.Methods: Patients with persistent, recurrent, or de novo Cushing’s disease (not candidates for surger...

ea0041gp154 | Pituitary - Clinical | ECE2016

Outcome predictors in profound hyponatremia – a prospective 12-month-follow-up study

Frech Nica , Winzeler Bettina , Nigro Nicole , Suter-Widmer Isabelle , Schutz Philipp , Arici Birsen , Bally Martina , Blum Claudine , Nickel Christian , Bingisser Roland , Bock Andreas , Huber Andreas , Muller Beat , Christ-Crain Mirjam

Introduction: Hyponatremia is the most common electrolyte abnormality in clinical practice and given its impact on mortality and morbidity a relevant medical condition. Nevertheless little is known about factors influencing long-term outcome.Methods: This is a prospective observational 12 months follow-up study of patients with profound hyponatremia (≤125 mmol/l) admitted to the medical emergency department of two tertiary care centers in Switzerla...

ea0041gp155 | Pituitary - Clinical | ECE2016

Plasma apelin concentrations in patients with polyuria-polydipsia syndrome

Urwyler Sandrine , Timper Katharina , Fenske Wiebke , de Mota Nadia , Blanchard Anne , Kuhn Felix , Frech Nica , Arici Birsen , Ruthishauser Jonas , Kopp Peter , Stettler Christoph , Muller Beat , Katan Mira , Llorens-Cortes Catherine , Christ-Crain Mirjam

Background: Apelin and arginine-vasopressin (AVP) are antagonists in the regulation of body fluid and osmotic homeostasis. So far there exist no data about apelin levels in patients with polyuria-polydipsia syndrome (PPS).Methods: Plasma apelin and copeptin concentrations were measured in 15 patients with complete central diabetes insipidus (cDI), in seven patients with complete nephrogenic diabetes insipidus (nDI) and 19 patients with primary polydipsia...

ea0041gp156 | Pituitary - Clinical | ECE2016

Natural history of a large cohort of pituitary incidentalomas in Italy

Tresoldi Alberto Stefano , Toini Alessandra , Profka Eriselda , Locatelli Marco , Lasio Giovanni Battista , Morenghi Emanuela , Spada Anna , Mantovani Giovanna , Lania Andrea Gerardo

In this observational, retrospective, multicenter study, we analyzed data from 300 patients with pituitary incidentaloma followed in two Italian Hospital Center. We observed a predominance of female patients (65%), with an a mean age at diagnosis of 49 years (higher in men than women, 57 vs 45 years old). The main reason to perform imaging were neurological symptoms not related to the presence of adenomas (56%). Most cases were microadenomas (56%), and macroadenomas were more ...

ea0041gp157 | Pituitary - Clinical | ECE2016

Prevalence of acromegaly in patients referred for sleep apnea syndrome (SAS): results of ACROSAS Study

Pepin J L , Galerneau L M , Borel A L , Chabre O , Sapene M , Stach B , Girey-Rannaud J , Tamisier R , Caron Ph

Introduction: Acromegaly is a rare disease (estimated prevalence 40–125 cases per million) resulting from GH/IGF1 hypersecretion, mostly by pituitary adenomas. SAS has a prevalence of up to 80% in acromegalic patients. The high frequency of acromegaly-related comorbidities and delayed diagnosis although effective treatments exist, make it necessary a screening of acromegaly in at risk populations.Aim: In a national multicenter study, to determine th...

ea0041gp158 | Pituitary - Clinical | ECE2016

Differentiated pharmacokinetics of levoketoconazole (COR-003), the single 2S,4R-enantiomer of ketoconazole, a new investigational drug for the treatment of Cushing’s syndrome

Thieroff-Ekerdt Ruth , Mould Diane

Ketoconazole is a 50/50 racemic mixture of two enantiomers (2S,4R and 2R,4S) used off label in the US for the treatment of endogenous Cushing’s syndrome by virtue of adrenal cortisol synthesis inhibition.COR-003 (levoketoconazole) is the more potent single (2S,4R) enantiomer of ketoconazole (KTZ) to inhibit adrenal cortisol synthesis and is currently being investigated in a multinational Phase 3 study for the treatment of endogenous Cushing’s s...